+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Angina Pectoris Drugs - Global Strategic Business Report

  • PDF Icon

    Report

  • 196 Pages
  • April 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5309394
The global market for Angina Pectoris Drugs is estimated at US$13.1 Billion in 2023 and is projected to reach US$17.8 Billion by 2030, growing at a CAGR of 3.9% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Beta Blockers segment, which is expected to reach US$8.7 Billion by 2030 with a CAGR of 4.3%. The Calcium Channel Blockers segment is also set to grow at 3.7% CAGR over the next 8 years.
  • Regional Analysis: Gain insights into the U.S. market, estimated at $4 Billion in 2023, and China, forecasted to grow at an impressive 3.8% CAGR to reach $3.1 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Angina Pectoris Drugs Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Angina Pectoris Drugs Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Angina Pectoris Drugs Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of major players such as Amgen, Inc., Bayer AG, Eli Lilly and Company, and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 46 Featured):

  • Amgen, Inc.
  • Bayer AG
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Merck & Co., Inc.
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer, Inc.
  • Sanofi SA

MarketGlass Platform

Our reports are enhanced by the MarketGlass platform, which brings together industry experts and influencers to provide high-quality, accurate insights. This unique platform allows us to gather comprehensive data and market perspectives, ensuring you receive the most reliable and detailed analysis available.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Angina Pectoris Drugs - Global Key Competitors Percentage Market Share in 2022 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • Global Economic Update
2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Angina Pectoris Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • Table 2: World Recent Past, Current & Future Analysis for Angina Pectoris Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 3: World Historic Review for Angina Pectoris Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 4: World 16-Year Perspective for Angina Pectoris Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
  • Table 5: World Recent Past, Current & Future Analysis for Beta Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 6: World Historic Review for Beta Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 7: World 16-Year Perspective for Beta Blockers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 8: World Recent Past, Current & Future Analysis for Calcium Channel Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 9: World Historic Review for Calcium Channel Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 10: World 16-Year Perspective for Calcium Channel Blockers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 11: World Recent Past, Current & Future Analysis for ACE Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 12: World Historic Review for ACE Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 13: World 16-Year Perspective for ACE Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 14: World Recent Past, Current & Future Analysis for Nitrates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 15: World Historic Review for Nitrates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 16: World 16-Year Perspective for Nitrates by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 17: World Recent Past, Current & Future Analysis for Anti-Platelets by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 18: World Historic Review for Anti-Platelets by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 19: World 16-Year Perspective for Anti-Platelets by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 20: World Recent Past, Current & Future Analysis for Other Therapeutic Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 21: World Historic Review for Other Therapeutic Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 22: World 16-Year Perspective for Other Therapeutic Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
  • Angina Pectoris Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • Table 23: USA Recent Past, Current & Future Analysis for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 24: USA Historic Review for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 25: USA 16-Year Perspective for Angina Pectoris Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes for the Years 2014, 2024 & 2030
CANADA
  • Table 26: Canada Recent Past, Current & Future Analysis for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 27: Canada Historic Review for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 28: Canada 16-Year Perspective for Angina Pectoris Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes for the Years 2014, 2024 & 2030
JAPAN
  • Angina Pectoris Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • Table 29: Japan Recent Past, Current & Future Analysis for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 30: Japan Historic Review for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 31: Japan 16-Year Perspective for Angina Pectoris Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes for the Years 2014, 2024 & 2030
CHINA
  • Angina Pectoris Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • Table 32: China Recent Past, Current & Future Analysis for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 33: China Historic Review for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 34: China 16-Year Perspective for Angina Pectoris Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes for the Years 2014, 2024 & 2030
EUROPE
  • Angina Pectoris Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • Table 35: Europe Recent Past, Current & Future Analysis for Angina Pectoris Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 36: Europe Historic Review for Angina Pectoris Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 37: Europe 16-Year Perspective for Angina Pectoris Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
  • Table 38: Europe Recent Past, Current & Future Analysis for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 39: Europe Historic Review for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 40: Europe 16-Year Perspective for Angina Pectoris Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes for the Years 2014, 2024 & 2030
FRANCE
  • Angina Pectoris Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • Table 41: France Recent Past, Current & Future Analysis for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 42: France Historic Review for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 43: France 16-Year Perspective for Angina Pectoris Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes for the Years 2014, 2024 & 2030
GERMANY
  • Angina Pectoris Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • Table 44: Germany Recent Past, Current & Future Analysis for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 45: Germany Historic Review for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 46: Germany 16-Year Perspective for Angina Pectoris Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes for the Years 2014, 2024 & 2030
ITALY
  • Table 47: Italy Recent Past, Current & Future Analysis for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 48: Italy Historic Review for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 49: Italy 16-Year Perspective for Angina Pectoris Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes for the Years 2014, 2024 & 2030
UNITED KINGDOM
  • Angina Pectoris Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • Table 50: UK Recent Past, Current & Future Analysis for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 51: UK Historic Review for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 52: UK 16-Year Perspective for Angina Pectoris Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes for the Years 2014, 2024 & 2030
REST OF EUROPE
  • Table 53: Rest of Europe Recent Past, Current & Future Analysis for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 54: Rest of Europe Historic Review for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 55: Rest of Europe 16-Year Perspective for Angina Pectoris Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes for the Years 2014, 2024 & 2030
ASIA-PACIFIC
  • Angina Pectoris Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • Table 56: Asia-Pacific Recent Past, Current & Future Analysis for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 57: Asia-Pacific Historic Review for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 58: Asia-Pacific 16-Year Perspective for Angina Pectoris Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes for the Years 2014, 2024 & 2030
REST OF WORLD
  • Table 59: Rest of World Recent Past, Current & Future Analysis for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 60: Rest of World Historic Review for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 61: Rest of World 16-Year Perspective for Angina Pectoris Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes for the Years 2014, 2024 & 2030
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Amgen, Inc.
  • Bayer AG
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Merck & Co., Inc.
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer, Inc.
  • Sanofi SA

Table Information